Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1095486#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B190957.
- aggregation creator B190958.
- aggregation creator B190959.
- aggregation creator B190960.
- aggregation creator B190961.
- aggregation creator B190962.
- aggregation creator B190963.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1095486.bibtex.
- aggregation hasFormat 1095486.csv.
- aggregation hasFormat 1095486.dc.
- aggregation hasFormat 1095486.didl.
- aggregation hasFormat 1095486.doc.
- aggregation hasFormat 1095486.json.
- aggregation hasFormat 1095486.mets.
- aggregation hasFormat 1095486.mods.
- aggregation hasFormat 1095486.rdf.
- aggregation hasFormat 1095486.ris.
- aggregation hasFormat 1095486.txt.
- aggregation hasFormat 1095486.xls.
- aggregation hasFormat 1095486.yaml.
- aggregation isPartOf urn:issn:1462-0324.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Vaccinations in patients with immune-mediated inflammatory diseases".
- aggregation abstract "Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased risk of infection, partially because of the disease itself, but mostly because of treatment with immunomodulatory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccination coverage in IMID patients is surprisingly low. This review summarizes current literature data on vaccine safety and efficacy in IMID patients treated with immunosuppressive or immunomodulatory drugs and formulates best-practice recommendations on vaccination in this population. Especially in the current era of biological therapies, including TNF-blocking agents, special consideration should be given to vaccination strategies in IMID patients. Clinical evidence indicates that immunization of IMID patients does not increase clinical or laboratory parameters of disease activity. Live vaccines are contraindicated in immunocompromized individuals, but non-live vaccines can safely be given. Although the reduced quality of the immune response in patients under immunotherapy may have a negative impact on vaccination efficacy in this population, adequate humoral response to vaccination in IMID patients has been demonstrated for hepatitis B, influenza and pneumococcal vaccination. Vaccination status is best checked and updated before the start of immunomodulatory therapy: live vaccines are not contraindicated at that time and inactivated vaccines elicit an optimal immune response in immunocompetent individuals.".
- aggregation authorList BK450036.
- aggregation endPage "1827".
- aggregation issue "10".
- aggregation startPage "1815".
- aggregation volume "49".
- aggregation aggregates 1100954.
- aggregation isDescribedBy 1095486.
- aggregation similarTo keq183.
- aggregation similarTo LU-1095486.